(Q37012207)

17 August 2017

title

Ursodeoxycholic acid: Mechanism of action and novel clinical applications (English)

1 reference

17 August 2017

Tadashi Ikegami

1

1 reference

17 August 2017

Yasushi Matsuzaki

series ordinal

2

1 reference

17 August 2017

publication date

23 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

38

1 reference

17 August 2017

issue

2

1 reference

17 August 2017

page(s)

123-131

1 reference

Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Bile salt transporters: molecular characterization, function, and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Trafficking of the bile salt export pump from the Golgi to the canalicular membrane is regulated by the p38 MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Decreased glucagon responsiveness by bile acids: a role for protein kinase Calpha and glucagon receptor phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Cyclic adenosine monophosphate-mediated protection against bile acid-induced apoptosis in cultured rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Cellular stress response and apoptosis in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Unconjugated secondary bile acids in the serum of patients with colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Ursodeoxycholic acid can suppress deoxycholic acid-induced apoptosis by stimulating Akt/PKB-dependent survival signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Selective preservation of protein kinase C-zeta in the chemoprevention of azoxymethane-induced colonic tumors by piroxicam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Treatment of nonalcoholic fatty liver: present and emerging therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00297.X

10.1111/J.1872-034X.2007.00297.X

21 January 2018

Identifiers

DOI

1 reference

release_jpmpsckhlna4ddir4orkrim2wa

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jpmpsckhlna4ddir4orkrim2wa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference